Effect of hyoscine butylbromide on cervical dilation during labor

• Published in: Medicina Universitaria 2015-01, Vol.17 (66), p.30-33
• Main Authors: Treviño-Salinas, E.M., Castillo-Martín del Campo, G.E., Ayuzo-del Valle, C., Guzmán-López, A., Soria-López, J.A., Iglesias-Benavides, J.L., Ambriz-López, R.
• Format: Article
• Language: English
• Subjects: Labor; Obstetrics; Oxytocics
• ISSN: 1665-5796; 1665-5796
• DOI: 10.1016/j.rmu.2015.01.001

To compare the effects of intravenous hyoscine butylbromide versus placebo on the duration of labor in term pregnancies. 86 patients were selected and randomly assigned to receive intravenous hyoscine butylbromide (20mg twice) (n=43) or an intravenous placebo (saline solution 10cc) (n=43). We evaluated maternal adverse effects, effects on neonatal Apgar score, cervical dilatation 1h after drug administration and the interval between the onset of labor and delivery. No significant differences were observed in the duration of phases of labor between the two groups. No significant differences were found between the groups in Apgar scores at 1 and 5min. No maternal adverse effects were observed or reported due to the use of hyoscine butylbromide or the placebo. On the first phase of primigravidas it shortens the first labor phase up to 159.1±84min vs. the control group (p=0.002). Hyoscine butylbromide oxytocin shortens the duration of labor in term primigravida pregnancies. No side effects were reported.